Top Markets
#1 MowCat MowCat +48.93%
#2 Velvet Velvet +25.75%
#3 Bermuda Shorts Bermuda Shorts +24.20%
#4 Quack AI Quack AI +22.15%
#5 Audiera Audiera +19.74%
#6 Derive Derive +19.65%
#7 MarsCoin MarsCoin +14.23%
#8 Biconomy Biconomy +13.76%
#9 aPriori aPriori +13.71%
#10 Geodnet Geodnet +13.43%
Coin of the day
MowCat MowCat
Innstillinger
Språk
NORSK
Valuta
USD
Tema
Graybug Vision, Inc. Graybug Vision, Inc.

Graybug Vision, Inc.

GRAY
Rangering i aksjer #35305
Graybug Vision, Inc. is a biopharmaceutical company currently in its clinical... Graybug Vision, Inc. is a biopharmaceutical company currently in its clinical development phase, dedicated to creating treatments for conditions affecting the eye's retina and optic nerve. Its flagship therapeutic, GB-102, is an injectable microparticle formulation of sunitinib administered directly into the eye. This compound is progressing through Phase I/IIa and IIb clinical trials for wet age-related macular degeneration, while also undergoing Phase IIa trials for diabetic macular edema. Furthermore, GB-102 is being explored as a treatment for diabetic retinopathy. The company's pipeline also includes GB-401, an intraocular implant designed to deliver a beta-adrenergic receptor inhibitor, intended for the management of primary open-angle glaucoma. Initially established as Graybug LLC in 2011, the firm rebranded to Graybug Vision, Inc. in 2016 and is headquartered in Redwood City, California.
Aksjekurs
$2.70
Sist synkronisert: 2023-05-17
Markedsverdi
$4.13M
Endring (1 dag)
0.00%
Endring (1 år)
0.00%
Land
US
Handel Graybug Vision, Inc. (GRAY)

Kategori

Healthcare
Inntekter for Graybug Vision, Inc. (GRAY)
Inntekter i 2026 TTM: 0
Ifølge Graybug Vision, Inc. sine nyeste økonomiske rapporter er selskapets nåværende resultat 0. I 2026 hadde selskapet et resultat på 0, lik resultatet i 2026, som var 0. Resultatet som vises på denne siden er resultat før renter og skatt, eller EBIT.
Inntektshistorikk for Graybug Vision, Inc. fra 2026 til 2026
Inntekter ved slutten av hvert år
År Inntekter Endre
Ikke nok data for de angitte datoene.
Inntekter for lignende selskaper eller konkurrenter
Selskap Inntekter Forskjell i inntekter Land
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.27B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.95B -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
- -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
$3.01B -
BE